As of Wednesday, Dec. 31, the moon phase is Waxing Gibbous. According to NASA's Daily Moon Observation, 88% of the moon will ...

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...

SEBI Grade A Admit Card 2025-26 is now available. Download the Phase 1 call letter and check exam details, instructions, ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Flow Foundation has entered phase two of its recovery after a $3.9 million exploit hit the network on December 27, 2025.

Phase 3 clinical trials follow phase 1 and 2 clinical trials. In a phase 1 clinical trial, the tolerability and safety of the new drug is studied, usually in a small number of healthy volunteers.

A phase 4 clinical trial begins after a drug has been approved for use in the general population following phase 1, 2 and 3 trials to rigorously test its efficacy and safety. In phase 1 clinical ...

At its Dec. 16 meeting, the Jackson City Council unanimously approved the final change order for Phase 1A, authorizing an ...